A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis

Fatemeh Yaghoubi ¹ * , Farrokhleghah Ahmadi ¹, Mahboub Lesanpezeshki ¹, Mitra Mahdavi Mazde ¹

Cited by CrossRef: 3

1- Alimohammadi N, Javadian P, Malekpour A, Tahmasebian S. Association of serum fibroblast growth factor 23 with calcium metabolism in patients with end-stage renal disease undergoing hemodialysis. J Nephropathol. 2017;6(4):352 [Crossref]

2- Mohammad W, Ahmad A, Sayed N. Association of serum fibroblast growth factor-23 with conventional cardiovascular risk factors in hemodialysis patients. 2017;17(4):115 [Crossref]

3- Kanda E, Ai M, Okazaki M, Yoshida M, Maeda Y, Shimosawa T. Association of High-Density Lipoprotein Subclasses with Chronic Kidney Disease Progression, Atherosclerosis, and Klotho. PLoS ONE. 2016;11(11):e0166459 [Crossref]

4- Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur A, Gruson D. FGF23: Clinical usefulness and analytical evolution. Clinical Biochemistry. 2019;66:1 [Crossref]